Monotherapy with Lanreotide Depot for Acromegaly: Long-term Clinical Experience in a Pituitary Center

Overview

Journal Pituitary

Specialty Endocrinology

Date 2016 May 9

PMID 27155600

Citations 4

Authors

Babak Torabi Sagvand

Shafaq Khairi

Arezoo Haghshenas

Brooke Swearingen

Nicholas A Tritos

Karen K Miller

Anne Klibanski

Lisa B Nachtigall

Affiliations

Soon will be listed here.

Abstract

Purpose: Long-acting somatostatin analogs are one of the main classes of medical therapy used for acromegaly and most patients require ongoing treatment. Few studies have evaluated the long-term efficacy and safety of lanreotide depot beyond 2 years. The goal of this study was to provide a long-term longitudinal assessment of efficacy and safety of lanreotide depot in lanreotide responders compared to a surgically cured control group.

Methods: In this retrospective longitudinal case-control study, patients with acromegaly receiving lanreotide depot monotherapy continuously for at least 24 months (N = 24) and surgically cured patients (N = 39) were compared. Serum IGF-1, pituitary MRIs, lanreotide dose, co-morbidities and adverse effects were assessed longitudinally.

Results: In the lanreotide group, IGF-1 remained normal and unchanged over 6 years; comparable to the surgery only group. There was no difference in prevalence of normal IGF-1 between the lanreotide and surgery only groups at 6 months (100 vs. 97 %), 6 years (89 vs. 90 %) and at last follow-up (96 vs. 92 %). Tumor size remained stable (79 %) or decreased (21 %) in the lanreotide group. In the surgery only group, tumor size remained unchanged in all patients. Hemoglobin A1C did not differ between lanreotide and surgery only groups (baseline 5.8 vs. 6.1 %; last follow-up 6.0 vs. 5.7 %). Two (8 %) of the lanreotide and none of the surgery only group developed new diabetes mellitus.

Conclusion: Lanreotide depot maintains normalization of IGF-1 in 89 % of responders after 6 years, comparable to surgically cured controls, and controlled tumor size in all without significant adverse effects.

Citing Articles

Secondary diabetes mellitus in acromegaly.

Moustaki M, Paschou S, Xekouki P, Kotsa K, Peppa M, Psaltopoulou T Endocrine. 2023; 81(1):1-15.

PMID: 36882643 PMC: 10239382. DOI: 10.1007/s12020-023-03339-1.

Biochemical Control in Acromegaly With Multimodality Therapies: Outcomes From a Pituitary Center and Changes Over Time.

Ghajar A, Jones P, Guarda F, Faje A, Tritos N, Miller K J Clin Endocrinol Metab. 2019; 105(3).

PMID: 31701145 PMC: 8660161. DOI: 10.1210/clinem/dgz187.

Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment.

Ferrau F, Albani A, Ciresi A, Giordano C, Cannavo S Front Endocrinol (Lausanne). 2018; 9:358.

PMID: 30034367 PMC: 6043782. DOI: 10.3389/fendo.2018.00358.

How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review.

van Esdonk M, van Zutphen E, Roelfsema F, Pereira A, van der Graaf P, Biermasz N Pituitary. 2018; 21(3):310-322.

PMID: 29605877 PMC: 5942341. DOI: 10.1007/s11102-018-0884-4.

References

Paisley A, Roberts M, Trainer P . Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clin Endocrinol (Oxf). 2007; 66(5):723-6. DOI: 10.1111/j.1365-2265.2007.02811.x. View

Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R . Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol. 2004; 151(3):317-24. DOI: 10.1530/eje.0.1510317. View

Flogstad A, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C . Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab. 1997; 82(1):23-8. DOI: 10.1210/jcem.82.1.3572. View

Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V . Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001; 86(6):2779-86. DOI: 10.1210/jcem.86.6.7556. View

Maiza J, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M . Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf). 2007; 67(2):282-9. PMC: 1974833. DOI: 10.1111/j.1365-2265.2007.02878.x. View

Grottoli S, Celleno R, Gasco V, Pivonello R, Caramella D, Barreca A . Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study. J Endocrinol Invest. 2006; 28(11):978-83. DOI: 10.1007/BF03345335. View

Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn J . Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf). 2006; 64(2):209-14. DOI: 10.1111/j.1365-2265.2006.02450.x. View

Colao A, Auriemma R, Savastano S, Galdiero M, Grasso L, Lombardi G . Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab. 2009; 94(8):2907-14. DOI: 10.1210/jc.2008-2627. View

Ayuk J, Stewart S, Stewart P, Sheppard M . Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab. 2002; 87(9):4142-6. DOI: 10.1210/jc.2001-011913. View

10.

Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J . Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes. 2005; 113(3):139-44. DOI: 10.1055/s-2005-837520. View

11.

Katznelson L, Laws Jr E, Melmed S, Molitch M, Murad M, Utz A . Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99(11):3933-51. DOI: 10.1210/jc.2014-2700. View

12.

Wattson D, Tanguturi S, Spiegel D, Niemierko A, Biller B, Nachtigall L . Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys. 2014; 90(3):532-9. DOI: 10.1016/j.ijrobp.2014.06.068. View

13.

Cuttica C, Fazzuoli L, Cariola G, Carraro A, Porcella E, Giusti M . [Behavior of the pituitary-thyroid axis in acromegalic subjects during prolonged intermittent and pulsatile treatment with octreotide]. Recenti Prog Med. 1994; 85(1):7-12. View

14.

Howlett T, Willis D, Walker G, Wass J, Trainer P . Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf). 2013; 79(5):689-99. DOI: 10.1111/cen.12207. View

15.

Lancranjan I, Atkinson A . Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary. 2000; 1(2):105-14. DOI: 10.1023/a:1009980404404. View

16.

Attanasio R, Barausse M, Cozzi R . GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. J Endocrinol Invest. 2001; 24(4):209-16. DOI: 10.1007/BF03343849. View

17.

Colao A, Bronstein M, Freda P, Gu F, Shen C, Gadelha M . Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014; 99(3):791-9. PMC: 3965714. DOI: 10.1210/jc.2013-2480. View

18.

Carmichael J, Bonert V, Nuno M, Ly D, Melmed S . Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014; 99(5):1825-33. PMC: 4010703. DOI: 10.1210/jc.2013-3757. View

19.

Petit J, Biller B, Coen J, Swearingen B, Ancukiewicz M, Bussiere M . Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract. 2008; 13(7):726-34. DOI: 10.4158/EP.13.7.726. View

20.

Zeinalizadeh M, Habibi Z, Fernandez-Miranda J, Gardner P, Hodak S, Challinor S . Discordance between growth hormone and insulin-like growth factor-1 after pituitary surgery for acromegaly: a stepwise approach and management. Pituitary. 2014; 18(1):48-59. DOI: 10.1007/s11102-014-0556-y. View